Hypoxia and Cyanosis¶
Chapter 42 | Part 2: Cardinal Manifestations and Presentation of Diseases · Part 2 – Cardinal Manifestations & Presentation · Chapter 42
Key Clinical Points¶
- Cyanosis becomes apparent when the concentration of reduced hemoglobin in capillary blood exceeds 40 g/L (4 g/dL).
- Hypoxia-inducible factor-1 (HIF-1) governs the upregulation of glycolytic enzymes, glucose transporters (Glut-1, Glut-2), VEGF, and erythropoietin.
- High-altitude illness develops at ≈3000 m (≈10,000 ft) where alveolar P_O2 decreases to ≈60 mmHg.
- Anemic hypoxia: PaO_2 is normal, but absolute O2 transport is diminished; cyanosis is often absent due to low total hemoglobin.
- Cyanide poisoning causes histotoxic hypoxia by impairing electron transport in mitochondria, limiting oxidative phosphorylation.
- Central cyanosis is caused by decreased arterial oxygen saturation (SaO_2) or abnormal hemoglobin derivatives (e.g., methemoglobin or sulfhemoglobin).
- Peripheral cyanosis is due to slowing of blood flow and abnormally great extraction of O2 from normally saturated arterial blood.
- High-altitude cerebral edema (HACE) is manifest by severe headache and papilledema and can cause coma.
- In patients with severe anemia, even marked arterial desaturation may not display cyanosis due to low absolute quantity of reduced hemoglobin.
- Patients with marked polycythemia tend to be cyanotic at higher levels of SaO_2 than patients with normal hematocrit values.
1. DEFINITION & OVERVIEW¶
The fundamental purpose of the cardiorespiratory system is to deliver O_2 and nutrients to cells and to remove CO_2 and other metabolic products from them. Proper maintenance of this function depends on intact cardiovascular and respiratory systems, adequate red blood cells/hemoglobin, and a supply of inspired gas with sufficient O_2.
1.1 Hypoxia¶
• Definition: Hypoxia is a condition where decreased O_2 availability to cells typically results in an inhibition of oxidative phosphorylation and increased anaerobic glycolysis. ◦ Mechanism: Switch from aerobic to anaerobic metabolism (the Pasteur effect) → reduced yield of adenosine 5′-triphosphate (ATP) produced per mole of glucose.
1.2 Cyanosis¶
• Definition: Cyanosis refers to a bluish color of the skin and mucous membranes resulting from an increased quantity of reduced hemoglobin (i.e., deoxygenated hemoglobin) or of hemoglobin derivatives (e.g., methemoglobin or sulfhemoglobin) in the small blood vessels of those tissues. ◦ Presentation: Usually most marked in the lips, nail beds, ears, and malar eminences.
2. EPIDEMIOLOGY¶
• Chronic Mountain Sickness: ◦ Develops in persons with chronic hypoxemia secondary to prolonged residence at a high altitude (>13,000 ft, 4200 m).
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Hypoxia is categorized into several types based on the underlying mechanism: Respiratory, Circulatory, High Altitude, Histotoxic, and Anemic.
3.1 Respiratory Hypoxia¶
• Mechanism: PaO_2 declines due to pulmonary disease or decreased FiO_2. ◦ Effect: The hemoglobin-oxygen (Hb-O) dissociation curve is displaced to the right, resulting in greater quantities of O_2 released at any level of tissue pO_2. ◦ Note: Arterial hypoxemia is more marked when PaO_2 depression results from pulmonary disease than from a decline in FiO_2.
3.2 Circulatory Hypoxia¶
• Generalized: Occurs in heart failure and most forms of shock. • Localized: Results from decreased perfusion due to arterial obstruction (e.g., localized atherosclerosis) or vasoconstriction (e.g., Raynaud's phenomenon). • Venous Obstruction: Leads to expansion of interstitial fluid → arteriolar compression → reduction of arterial inflow.
3.3 Hypoxia Secondary to High Altitude¶
• Mechanism: Rapid ascent to 3000 m (≈10,000 ft) → reduced FiO_2 → alveolar pO_2 drops to ≈60 mmHg. • Severity: At 5000 m, unacclimated individuals usually cease to be able to function normally due to changes in CNS function.
3.4 Increased $O_2$ Requirements¶
• Conditions: Fever or thyrotoxicosis. • Presentation: Skin is warm and flushed (increased cutaneous blood flow) → cyanosis is usually absent.
3.5 Improper Oxygen Utilization (Histotoxic Hypoxia)¶
• Cause: Cyanide and similar poisons impair electron transport in mitochondria, limiting oxidative phosphorylation. • Result: Tissues unable to use O_2 → venous blood tends to have a high O_2 tension.
3.6 Anemic Hypoxia¶
• Mechanism: Reduced hemoglobin concentration → diminished O_2-carrying capacity. • Difference: PaO_2 is normal, but absolute O_2 transport per unit volume of blood is diminished. • Clinical Sign: Cyanosis often absent due to low total hemoglobin.
3.7 Carbon Monoxide (CO) Intoxication¶
• Mechanism: Hemoglobin binds CO (carboxy-hemoglobin [COHb]) → unavailable for O_2 transport. • Effect: Presence of COHb shifts the Hb-O dissociation curve to the left → O_2 is unloaded only at lower tensions.
3.8 Hypoxia Secondary to Right-to-Left Shunting¶
• Mechanism: Congenital cardiac malformations (e.g., tetralogy of Fallot, transposition of the great arteries, atrial or ventricular septal defect, patent ductus arteriosus, and Eisenmenger's syndrome). • Result: PaO_2 cannot be restored to normal with inspiration of 100% O_2.
4. CLINICAL FEATURES¶
Changes in the central nervous system (CNS) function, particularly the higher centers, are especially important consequences of hypoxia.
4.1 High-Altitude Illness¶
• Symptoms: Headache (cerebral vasodilation), gastrointestinal symptoms, dizziness, insomnia, fatigue, or somnolence. • HAPE: Pulmonary arterial and sometimes venous constriction → capillary leakage → high-altitude pulmonary edema → intensified hypoxia → further vasoconstriction. • HACE: Rare; manifest by severe headache and papilledema → can cause coma. • Critical Failure: Severe hypoxia affects brainstem regulatory centers → respiratory failure → death.
4.2 Cardiovascular Effects¶
• Acute Phase: Chemoreceptor reflex → venoconstriction and systemic arterial vasodilation → transiently increased myocardial contractility. • Chronic/Prolonged Phase: Decreased myocardial contractility. • Comorbidities: ◦ Heart Disease: Increased demand for cardiac output → may precipitate congestive heart failure. ◦ Ischemic Heart Disease: Reduced PaO_2 → intensified myocardial ischemia → impaired left ventricular function.
4.3 Cyanosis Presentation¶
• Central Cyanosis: SaO_2 is reduced or abnormal hemoglobin derivative is present; mucous membranes and skin are both affected. • Peripheral Cyanosis: Slowed blood flow and abnormally great extraction of O_2 from normally saturated arterial blood (e.g., cold exposure, shock, congestive failure, peripheral vascular disease). ◦ Note: In peripheral cases, the mucous membranes of the oral cavity, including the sublingual mucosa, may be spared.
5. DIFFERENTIAL DIAGNOSIS¶
Decreased SaO_2 results from a marked reduction in the PaO_2. This reduction may be brought about by a decline in the FiO_2 without sufficient compensatory alveolar hyperventilation.
5.1 Central Cyanosis Causes¶
• Environmental: Decreased atmospheric pressure (high altitude). • Pulmonary: Impaired pulmonary function, alveolar hypoventilation, inhomogeneity in pulmonary ventilation and perfusion, impaired oxygen diffusion. • Anatomic/Congenital: Anatomic shunts, congenital heart disease, pulmonary arteriovenous fistulas, multiple small intrapulmonary shunts. • Hemoglobin Abnormalities: Methemoglobinemia, sulfhemoglobinemia, carboxyhemoglobinemia (not true cyanosis), hemoglobin with low affinity for oxygen.
5.2 Peripheral Cyanosis Causes¶
• Circulatory: Reduced cardiac output. • Environmental/Local: Cold exposure, redistribution of blood flow from extremities. • Obstructive: Arterial obstruction, venous obstruction.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis is primarily based on clinical presentation and the identification of specific thresholds for cyanosis and altitude.
6.1 Diagnostic Criteria for Cyanosis¶
• Cyanosis Threshold: Measurement of capillary blood → if concentration of reduced hemoglobin exceeds 40 g/L (4 g/dL) → cyanosis is present.
6.2 High-Altitude Diagnostic Thresholds¶
• 3000 m (≈10,000 ft): PaO_2 drops to ≈60 mmHg. • 5000 m: Unacclimated individuals typically cannot function normally.
7. MANAGEMENT & TREATMENT¶
Management focuses on the underlying cause of hypoxia or cyanosis.
7.1 Respiratory Hypoxia Management¶
- Primary Action: Correct underlying pulmonary disease.
- Supportive: Improve ventilation.
7.2 High-Altitude Illness Management¶
- Standard Treatment: Descent to lower altitude and administration of supplemental oxygen.
- HAPE Management: Descent and oxygen are critical.
- HACE Management: Dexamethasone may be used.
7.3 Hemoglobin Abnormalities¶
- Treatment: Specific antidotes or transfusions as required.
8. PROGNOSIS & COMPLICATIONS¶
• High-Altitude Complications: ◦ HAPE → intensifies hypoxia → promotes vasoconstriction. ◦ HACE → can cause coma. ◦ Severe Hypoxia → brainstem involvement → respiratory failure → death. • Chronic Mountain Sickness: ◦ Characterized by right ventricular enlargement (secondary to pulmonary hypertension) and potential stupor.
9. SPECIAL CONSIDERATIONS¶
• Cardiac Disease: Patients with underlying heart disease are at higher risk for congestive heart failure due to increased demand for cardiac output during hypoxia. • Ischemic Heart Disease: Reduced PaO_2 may intensify myocardial ischemia and further impair left ventricular function.
10. KEY PEARLS & CLINICAL TRAPS¶
• Detection: Cyanosis is often detected by family members before the patient. • Quantification: The absolute quantity of reduced hemoglobin is more important than the relative quantity. • Anemia vs. Polycythemia: ◦ Anemia masks cyanosis (due to low total Hb). ◦ Polycythemia enhances cyanosis (higher concentration of Hb at higher SaO_2). • Carbon Monoxide: Carboxyhemoglobinemia presents with a cherry-colored flush, not true cyanosis.
Reference Tables¶
TABLE 42-1 Causes of Cyanosis Central Cyanosis Decreased arterial oxygen saturation¶
Harrison's 22e, p.278
- Central Cyanosis
- Decreased arterial oxygen saturation
Decreased atmospheric pressure—high altitude
Impaired pulmonary function
Alveolar hypoventilation
Inhomogeneity in pulmonary ventilation and perfusion (perfusion of
hypoventilated alveoli)
Impaired oxygen diffusion
Anatomic shunts
Certain types of congenital heart disease
Pulmonary arteriovenous fistulas
Multiple small intrapulmonary shunts
Hemoglobin with low affinity for oxygen
Hemoglobin abnormalities
Methemoglobinemia—hereditary, acquired
Sulfhemoglobinemia—acquired
Carboxyhemoglobinemia (not true cyanosis) - Peripheral Cyanosis
- Reduced cardiac output
Cold exposure
Redistribution of blood flow from extremities
Arterial obstruction
Venous obstruction